Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Other Non-Current Assets (2019 - 2026)

Atea Pharmaceuticals' Other Non-Current Assets history spans 8 years, with the latest figure at $3.0 million for Q1 2026.

  • Quarterly Other Non-Current Assets fell 30.63% to $3.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Mar 2026, down 30.63% year-over-year, with the annual reading at $3.1 million for FY2025, 1491.88% up from the prior year.
  • Other Non-Current Assets came in at $3.0 million for Q1 2026, down from $3.1 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $5.5 million in Q3 2025 to a low of $197000.0 in Q4 2024.
  • The 5-year median for Other Non-Current Assets is $1.4 million (2023), against an average of $1.7 million.
  • Year-over-year, Other Non-Current Assets plummeted 85.89% in 2024 and then surged 1491.88% in 2025.
  • Atea Pharmaceuticals' Other Non-Current Assets stood at $198000.0 in 2022, then surged by 605.05% to $1.4 million in 2023, then tumbled by 85.89% to $197000.0 in 2024, then soared by 1491.88% to $3.1 million in 2025, then decreased by 2.81% to $3.0 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Other Non-Current Assets are $3.0 million (Q1 2026), $3.1 million (Q4 2025), and $5.5 million (Q3 2025).